Core Insights - H.R. 7091 is a bipartisan legislation aimed at expanding research and development for emerging therapies for Alcohol Use Disorder (AUD) among U.S. veterans, recognizing the significant prevalence of AUD in this population [1][2][5] Group 1: Legislative Context - The legislation specifically includes AUD as a condition eligible for expanded research and development, supporting non-abstinence based treatment options [3] - H.R. 7091 aligns with the U.S. Government's updated definition of recovery, which emphasizes harm reduction and reductions in heavy drinking as meaningful clinical outcomes [3][5] Group 2: Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for addiction, with its lead investigational product candidate, AD04, targeting AUD through a genetically targeted therapy approach [4][7] - AD04 follows a non-abstinence based treatment strategy and aims to reduce heavy drinking days, consistent with FDA-supported endpoints [4][6] Group 3: Market Implications - The introduction of H.R. 7091 is seen as a significant step forward for veterans needing additional treatment options for AUD, reflecting bipartisan recognition of the need for innovative approaches to Substance Use Disorders [5][6] - Adial believes that the legislation reinforces federal support for harm reduction-based treatment paradigms, potentially advancing the development of therapies like AD04 [6]

Core Insights - 2025 was a pivotal year for Adial Pharmaceuticals, marked by advancements in the development of AD04, including positive pharmacokinetic results and a productive End-of-Phase 2 meeting with the FDA, which validated the company's clinical and regulatory approach [3] - The company is encouraged by bipartisan support in the U.S. Senate for expanding clinical trial endpoints beyond strict abstinence, aligning with the patient-centered approach of AD04 [3] - Recent FDA discussions indicate a potential shift towards more flexible development frameworks, allowing for approval based on one well-controlled study plus confirmatory evidence, which could significantly reduce late-stage clinical development costs [3] Regulatory Progress - Achieved positive results from the AD04-103 pharmacokinetics study, supporting AD04's pharmacologic profile and regulatory strategy [4] - Received a positive response from the FDA regarding the proposed in vitro bridging strategy [4] - Successfully completed the End-of-Phase 2 meeting, advancing regulatory alignment towards Phase 3 development [4] Intellectual Property Expansion - Strengthened intellectual property coverage with multiple U.S. patents issued for genotype-specific treatment of opioid disorders and expanded genetic-based approaches for treating Alcohol Use Disorder (AUD) [4] - Filed a Patent Cooperation Treaty application to protect core assets and extend international exclusivity by 14 years through at least 2045 [4][8] Strategic Partnerships - Engaged Cytel Inc. for advanced clinical trial design to support AD04 Phase 3 planning [4] - Partnered with Genomind for precision medicine testing solutions aligned with genotype-guided therapeutic strategy [4] - Entered into a collaboration framework agreement with Molteni Farmaceutici for the commercialization of AD04 in Europe, with a potential value of nearly $60 million [5][6] Financial Overview - Cash and cash equivalents were $5.9 million as of December 31, 2025, compared to $3.8 million as of December 31, 2024, expected to fund operations into the second half of 2026 [12] - Research and development expenses decreased by approximately $609 thousand (19%) in 2025 compared to 2024, primarily due to lower clinical activity [12] - General and administrative expenses increased by approximately $125,000 (2%) in 2025, mainly due to higher compensation expenses [12] - Net loss was $8.0 million for 2025, a decrease from $13.2 million in 2024, driven by lower R&D spending and a one-time non-cash inducement expense in 2024 [12]

Core Insights - Adial Pharmaceuticals has entered into a collaboration framework agreement with Molteni Farmaceutici for the exclusive commercialization of AD04 in Europe, marking a significant step towards establishing a European commercial pathway for the drug [1][3]. Collaboration Framework - The collaboration framework outlines strategic and financial parameters for the partnership, including clinical, regulatory, manufacturing, and commercial terms, with Molteni granted exclusivity to evaluate project feasibility and conduct due diligence [2]. - The definitive agreement is expected to include an upfront payment, milestone payments based on development and commercial progress, and tiered royalties on European AD04 net sales, with a total potential value estimated at nearly $60 million [3]. Company Background - Molteni, established in 1892, is a specialty pharmaceutical company with expertise in pain management and Substance Use Disorder (SUD) treatment, possessing integrated capabilities across manufacturing, R&D, regulatory, and commercialization [4]. Strategic Importance - The agreement is seen as a significant milestone for Adial, as it leverages Molteni's established infrastructure in Europe to advance AD04 towards commercialization [5]. - Adial has restructured its clinical development program for AD04, focusing on genotype-driven development to enhance efficacy and reduce costs, while also preparing for simultaneous regulatory strategies in the U.S. and Europe [5]. Manufacturing and Supply Chain - Adial has secured agreements with leading U.S. manufacturers to ensure a secure supply chain for AD04, supporting both clinical trials and potential commercialization [5]. Intellectual Property - A new patent has been filed by Adial, which, if granted, could extend the Loss of Exclusivity (LOE) date by an additional 14 years, providing over a decade of potential commercial exclusivity post-launch [5]. Genetic Screening Improvement - The company has improved its genetic screening process by replacing the blood draw with a cost-effective cheek swab test, facilitating easier adoption in clinical practice [6]. Future Plans - Adial is actively engaging with potential commercial partners in the U.S. as it prepares to initiate its pivotal Phase 3 program for AD04 [6].

Company Highlights - Adial Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, with the closing bid price at $1.00 or greater for 10 consecutive business days from February 6 to February 20, 2026 [1][2] - The resolution of the compliance issue is considered an important milestone as the company advances its lead product, AD04, toward a pivotal Phase 3 clinical trial program [3] Product Development - AD04 is a genetically targeted serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder (AUD) in heavy drinking patients [4] - The recent ONWARD Phase 3 clinical trial for AD04 showed promising results in reducing drinking among heavy drinkers, with no significant safety or tolerability concerns reported [4] - The company is also exploring the potential of AD04 to treat other addictive disorders, including Opioid Use Disorder, gambling, and obesity [4] Strategic Partnerships - Adial is currently engaged in advanced strategic partnering discussions that may support the next phase of AD04's development and future commercialization in key markets [3]

Core Insights - The FDA's recent policy shift allows for drug approval based on one adequate and well-controlled clinical investigation plus confirmatory evidence, rather than the traditional requirement of two pivotal studies, which could significantly lower costs and accelerate the NDA submission process for Adial's lead drug candidate, AD04 [1][2][3] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders, with its lead investigational drug candidate, AD04, targeting Alcohol Use Disorder (AUD) in heavy drinking patients [5] - AD04 is a genetically targeted serotonin-3 receptor antagonist, and the company is preparing for a new Phase 3 clinical trial program, utilizing a proprietary diagnostic genetic test to identify target genotypes [5] Regulatory Impact - The FDA's modernization of evidentiary standards emphasizes trial quality and confirmatory support over the number of trials, which aligns with Adial's strategy to potentially conduct a single pivotal trial for AD04 [2][4] - Cary Claiborne, CEO of Adial, highlighted that this regulatory change could transform the company's development strategy by significantly lowering Phase 3 costs and improving capital efficiency [4] Clinical Development Strategy - Adial intends to engage closely with the FDA to align its evidentiary strategy for AD04 with current regulatory standards, which may enhance the strategic and economic profile of the asset [4][7] - The company believes that AD04 has the potential to treat other addictive disorders beyond AUD, including Opioid Use Disorder, gambling, and obesity [5]

Group 1 - Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders [3] - The company's lead investigational new drug, AD04, is a serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder (AUD) in heavy drinking patients [3] - The ONWARD™ pivotal Phase 3 clinical trial for AD04 showed promising results in reducing drinking among heavy drinking patients without significant safety or tolerability concerns [3] Group 2 - Cary Claiborne, CEO of Adial, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 2:40 p.m. Eastern Time [2] - The presentation will be available for live webcast and replay on the company's website [2] - Management will conduct one-on-one meetings with approved investors throughout the conference [2]

Core Insights - Adial Pharmaceuticals, Inc. has welcomed the recent passage of the 2026 Appropriations Bill, which includes directives for the FDA and NIDA to establish alternative clinical trial endpoints for substance use disorder treatments, including Alcohol Use Disorder (AUD) [1][2][5] Group 1: Legislative Impact - The legislation directs the FDA to consider non-abstinence-based endpoints such as reduced cravings and disorder severity, reflecting clinically meaningful improvements for patients [2][3] - This directive aligns with the NIAAA's updated definition of recovery, which emphasizes improvements in functioning and symptom reduction as valid treatment goals [3] Group 2: Company Strategy and Product Development - Adial's lead investigational therapy, AD04, is designed to treat AUD using a precision medicine approach, aligning with the newly established non-abstinence recovery outcomes [4][5] - The collaboration between federal agencies to define alternative endpoints is expected to strengthen the regulatory framework for innovative therapies like AD04, potentially accelerating development timelines and broadening clinical relevance [4][5] Group 3: Market Context - AUD remains a significant public health challenge, affecting millions with limited treatment options that achieve durable outcomes [5] - Adial believes that regulatory clarity around alternative endpoints will enhance the regulatory path for AD04 and support the company's strategy to address the unmet need in AUD with precision-based therapies [5][6]

Core Viewpoint - Adial Pharmaceuticals, Inc. will implement a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement and enhance its capital markets profile [1][3][4] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 27.8 million to about 1.1 million, while maintaining the ownership percentage of each shareholder [2] - The reverse stock split will take effect on February 5, 2026, at 11:59 p.m. Eastern Time, with trading on a split-adjusted basis starting February 6, 2026 [1][2] - There will be no change to the total number of authorized shares as per the Company's Certificate of Incorporation [2] Group 2: Strategic Intentions - The reverse stock split aims to bring the Company into compliance with Nasdaq's minimum bid price requirement of at least $1.00 per share [3] - The action is expected to make the bid price more attractive to a wider range of institutional and retail investors [3][4] - The Company remains optimistic about its future and is focused on advancing its lead product, AD04, for the treatment of Alcohol Use Disorder [4][5] Group 3: Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders [5] - The lead investigational drug, AD04, is a genetically targeted serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder in heavy drinking patients [5] - The Company plans to conduct a new Phase 3 clinical trial program for AD04, which has shown promising results in reducing drinking without significant safety concerns [5]

Core Viewpoint - Adial Pharmaceuticals, Inc. is implementing a 1-for-25 reverse stock split to strengthen its capital markets profile and comply with Nasdaq's minimum bid price requirement [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 27.8 million to about 1.1 million, while maintaining the ownership percentage of each shareholder [2]. - The reverse stock split will take effect on February 5, 2026, at 11:59 p.m. Eastern Time, with trading on a split-adjusted basis starting February 6, 2026 [1][2]. - There will be no change to the total number of authorized shares as per the Company's Certificate of Incorporation [2]. Group 2: Company Strategy and Future Outlook - The Company is optimistic about its future and is focused on advancing its lead product, AD04, a genetically targeted serotonin-3 receptor antagonist for treating Alcohol Use Disorder [3][4]. - Adial plans to conduct a new Phase 3 clinical trial program for AD04, targeting specific genotypes identified through its proprietary diagnostic genetic test [4]. - The Company believes that AD04 has the potential to treat other addictive disorders, including Opioid Use Disorder, gambling, and obesity [4].

Core Viewpoint - Adial Pharmaceuticals will implement a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement and enhance its capital markets profile, effective February 5, 2026 [1][3][4] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 27.8 million to about 1.1 million, while maintaining the ownership percentage of existing shareholders [2] - The new CUSIP number for the common stock post-split will be 00688A304, and trading on a split-adjusted basis will commence on February 6, 2026 [1][2] Group 2: Compliance and Market Strategy - The reverse split aims to ensure compliance with Nasdaq's requirement of a minimum bid price of $1.00 per share, making the stock more appealing to institutional and retail investors [3] - The company believes this action will strengthen its capital markets profile and create a more efficient public float, supporting broader investor interest [4] Group 3: Company Overview and Future Plans - Adial Pharmaceuticals is focused on developing treatments for addiction, with its lead product AD04 targeting Alcohol Use Disorder [5] - The company plans to conduct a new Phase 3 clinical trial for AD04, which has shown promising results in reducing drinking among heavy drinkers [5]